Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Do you treat early stage multifocal breast cancer similarly to single site lesion?
How does it affect your calculation of risk stratification?
Related Questions
Do you approach systemic therapy any differently for patients with locally advanced relapses of TNBC with metaplastic squamous differentiation, as opposed to patients with TNBC?
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
How would you manage a HR+/HER2+ breast cancer patient with no response during neoadjuvant TCHP?
How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?
Would you consider chemoimmunotherapy (CP-Keytruda-AC) in triple negative breast cancer if tumor is not palpable on physical exam?
How do you counsel pre-menopausal breast cancer patients about birth control?
What are your top takeaways from SABCS 2022?
What adjuvant treatment would you recommend for a microinvasive ER+ breast cancer with a high ki67?
For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?
Would you consider omitting platinum from neoadjuvant chemotherapy in women > 50 years of age with localized triple negative breast cancer?
